Drugs for Gastrointestinal Diseases Practice Questions

Q: Which of the following drugs does NOT decrease gastric acid secretion?

Sucralfate. **Explanation:** The correct answer is **Sucralfate** because it is a **cytoprotective agent**, not an antisecretory drug. It does not alter the pH of the gastric juice or inhibit the production of acid. **Why Sucralfate is correct:** Sucralfate is an aluminum salt of sulfated sucrose. In an acidic environment (pH < 4), it undergoes polymerization to form a sticky, viscous gel. This paste binds selectively to the exposed proteins (albumin, fibrinogen) in the ulcer base, creating a physical barrier against acid, pepsin, and bile. It "coats" the ulcer rather than stopping acid production. **Why the other options are incorrect:** * **Ranitidine:** Is an **$H_2$ receptor antagonist**. It competitively inhibits histamine at the $H_2$ receptors on gastric parietal cells, significantly decreasing basal and stimulated acid secretion. * **Omeprazole:** Is a **Proton Pump Inhibitor (PPI)**. It irreversibly inhibits the $H^+/K^+$-ATPase pump in the parietal cells, which is the final common pathway for acid secretion. It is the most potent acid suppressant. * **Pirenzepine:** Is a selective **$M_1$ anticholinergic** drug. It reduces gastric acid secretion by blocking $M_1$ receptors on paracrine cells, thereby reducing histamine release. **NEET-PG High-Yield Pearls:** * **Administration:** Sucralfate requires an acidic medium for activation; therefore, it should **not** be given simultaneously with antacids, $H_2$ blockers, or PPIs (take it 1 hour before meals). * **Side Effects:** The most common side effect of Sucralfate is **constipation** (due to the aluminum content). * **Drug Interactions:** It can adsorb other drugs (e.g., Tetracycline, Digoxin, Phenytoin), reducing their absorption. * **Pirenzepine** is rarely used clinically now due to the superior efficacy of PPIs but remains a classic pharmacological example of an $M_1$ blocker.

Q: Which of the following drugs used in the management of peptic ulcers can cause gynecomastia?

Cimetidine. **Explanation:** **Cimetidine** is a first-generation H2-receptor antagonist. It is the only drug in its class notorious for causing **gynecomastia** and erectile dysfunction. This occurs through two primary mechanisms: 1. **Anti-androgenic effect:** It binds to androgen receptors and inhibits the action of dihydrotestosterone (DHT). 2. **Hyperprolactinemia:** It inhibits the metabolism of estradiol and increases serum prolactin levels by inhibiting the breakdown of estrogen in the liver. **Analysis of Incorrect Options:** * **Sucralfate (A):** A physical mucosal protectant that forms a "sticky" polymer over the ulcer base. It is not absorbed systemically and has no hormonal side effects. * **Pirenzepine (C):** A selective M1-anticholinergic drug that reduces gastric acid secretion. Its side effects are typically atropine-like (dry mouth, blurred vision) rather than hormonal. * **Rabeprazole (D):** A Proton Pump Inhibitor (PPI). While PPIs are more potent than H2 blockers, they do not possess anti-androgenic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Enzyme Inhibition:** Cimetidine is a potent **Cytochrome P450 inhibitor**, leading to significant drug interactions (e.g., increasing levels of Warfarin, Phenytoin, and Theophylline). * **Newer H2 Blockers:** Ranitidine, Famotidine, and Roxatidine are more potent than Cimetidine and **do not** cause gynecomastia or significant P450 inhibition. * **Other Drugs causing Gynecomastia (Mnemonic: DISCO):** **D**igoxin, **I**soniazid, **S**pironolactone, **C**imetidine, **O**estrogens/Ketoconazole.

Q: Which drug is used to manage Cisplatin-induced nausea and vomiting occurring within 24 hours?

Ondansetron. ### Explanation **Correct Answer: C. Ondansetron** **Mechanism and Rationale:** Cisplatin is a highly emetogenic chemotherapy agent that triggers vomiting via two phases: **Acute** (within 24 hours) and **Delayed** (after 24 hours). * **Acute phase:** Mediated primarily by the release of **Serotonin (5-HT)** from enterochromaffin cells in the GI tract, which stimulates 5-HT3 receptors on vagal afferents. * **Ondansetron** is a selective **5-HT3 receptor antagonist** and is the first-line drug of choice for preventing acute chemotherapy-induced nausea and vomiting (CINV). **Analysis of Incorrect Options:** * **A & B (Aprepitant/Fosaprepitant):** These are **NK1 receptor antagonists**. While they are used in Cisplatin regimens, their primary role is in managing the **delayed phase** of vomiting (mediated by Substance P). They are usually combined with 5-HT3 antagonists and dexamethasone for highly emetogenic protocols. * **D (Promethazine):** This is a first-generation H1-antihistamine with dopamine-blocking properties. It is used for motion sickness or mild nausea but is **ineffective** against the potent emetogenic stimulus of Cisplatin. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice (DOC):** 5-HT3 antagonists (Ondansetron/Palonosetron) are the DOC for acute CINV and post-operative nausea/vomiting (PONV). 2. **Palonosetron:** A newer 5-HT3 antagonist with a longer half-life; it is the only drug in its class effective for *both* acute and delayed phases. 3. **Side Effects:** The most common side effects of Ondansetron are **headache** and **constipation**. It can also cause **QT interval prolongation**. 4. **Triple Therapy:** For highly emetogenic drugs like Cisplatin, the standard of care is a combination of a 5-HT3 antagonist + Dexamethasone + NK1 antagonist.

Q: A 27-year-old woman occasionally uses calcium carbonate for 'heartburn' symptoms after a large meal. What is the mechanism of action of the prescribed medication for an acid-peptic disorder?

Neutralizes gastric acid. **Explanation:** The patient is using **Calcium carbonate**, which belongs to the class of **Antacids**. These are weak bases that react with gastric hydrochloric acid (HCl) to form salt and water. **1. Why Option A is Correct:** The primary mechanism of antacids is the **neutralization of gastric acid**. By reacting with HCl, they increase the gastric pH. This reduction in acidity not only provides immediate relief from "heartburn" but also decreases the activity of pepsin (which is inactive above pH 4), thereby protecting the esophageal and gastric mucosa from acid-pepsin digestion. **2. Why the Other Options are Incorrect:** * **Option B (Binds to cysteine):** This refers to the mechanism of **Proton Pump Inhibitors (PPIs)** like Omeprazole. PPIs form a covalent disulfide bond with cysteine residues on the $H^+/K^+$-ATPase pump. * **Option C (Inhibits gastrin release):** While some drugs like Octreotide can inhibit gastrin, standard acid-peptic medications do not primarily work this way. Antacids may actually cause "acid rebound" by stimulating gastrin release due to the sudden rise in pH. * **Option D (Irreversible H1-receptor blockade):** This is incorrect on two counts. Drugs for acid-peptic disease target **H2-receptors** (e.g., Ranitidine), and this blockade is typically **reversible**. H1-blockers are used for allergies. **High-Yield Clinical Pearls for NEET-PG:** * **Milk-Alkali Syndrome:** Excessive intake of Calcium carbonate with calcium-rich foods can lead to hypercalcemia, metabolic alkalosis, and renal failure. * **Drug Interactions:** Antacids can adsorb or change the ionization of other drugs (e.g., Tetracyclines, Iron, Fluoroquinolones), reducing their absorption. Always maintain a 2-hour gap. * **Systemic vs. Non-systemic:** Sodium bicarbonate is systemic (absorbable), while Aluminum/Magnesium hydroxides and Calcium carbonate are largely non-systemic.

Q: Which of the following medications is used to treat opioid-induced constipation?

Alvimopan. **Explanation:** **1. Why Alvimopan is Correct:** Opioid-induced constipation (OIC) occurs because opioids stimulate **mu-opioid receptors** in the enteric nervous system, leading to decreased intestinal motility and increased fluid absorption. **Alvimopan** is a peripherally acting mu-opioid receptor antagonist (**PAMORA**). Its key feature is that it does not cross the blood-brain barrier. Therefore, it selectively blocks the constipating effects of opioids in the gut without reversing the central analgesic (pain-relieving) effects. It is specifically FDA-approved to accelerate gastrointestinal recovery following bowel resection. **2. Analysis of Incorrect Options:** * **A. Loperamide:** This is a peripheral mu-opioid agonist used to treat **diarrhea**. Giving it for OIC would worsen the constipation. * **B. Biperiden:** This is a centrally acting **anticholinergic** drug used primarily to treat Parkinsonism and extrapyramidal side effects of antipsychotics. * **C. Naltrexone:** While this is an opioid antagonist, it is **centrally acting**. If used for OIC, it would cross the blood-brain barrier and immediately precipitate withdrawal symptoms and reverse the patient's pain relief. **3. NEET-PG High-Yield Pearls:** * **Other PAMORAs:** Methylnaltrexone (subcutaneous) and Naloxegol (oral) are also used for OIC, especially in palliative care. * **Mechanism:** PAMORAs are "peripherally restricted," meaning they have high polarity or are substrates for P-glycoprotein, preventing CNS entry. * **Contraindication:** Alvimopan is generally restricted to short-term hospital use due to a potential risk of myocardial infarction with long-term use. * **First-line for OIC:** Usually stimulant laxatives (Senna/Bisacodyl) + stool softeners; PAMORAs are reserved for refractory cases.

Q: Which of the following is TRUE regarding anti-H. pylori therapy EXCEPT?

It is indicated in all patients with peptic ulcer disease.. ### Explanation **1. Why Option A is the Correct Answer (The "Except" Statement):** While *H. pylori* is a major cause of peptic ulcer disease (PUD), it is not the only cause. PUD can also be induced by **NSAIDs, Zollinger-Ellison Syndrome (gastrinoma), or stress**. Anti-*H. pylori* therapy is indicated **only** when the presence of the bacterium is confirmed via diagnostic tests (e.g., Urea Breath Test, Stool Antigen, or Biopsy). Treating all PUD patients empirically without confirmation leads to unnecessary antibiotic use and resistance. **2. Analysis of Other Options:** * **Option B:** *H. pylori* is notorious for developing rapid resistance, especially to **Clarithromycin and Metronidazole**, if used as monotherapy. This is why multi-drug regimens (Triple or Quadruple therapy) are mandatory. * **Option C:** Gastric acid suppression (using PPIs) is crucial because: * It increases the stability and bioavailability of antibiotics (like Amoxicillin and Clarithromycin) which are acid-labile. * It raises the gastric pH to a level where *H. pylori* enters a replicative state, making it more susceptible to antibiotics. * **Option D:** Colloidal Bismuth Subcitrate (CBS) has direct antimicrobial activity and coats the ulcer base. However, it causes **blackening of stools/tongue** and has a metallic taste, leading to poor patient compliance. **3. Clinical Pearls for NEET-PG:** * **Standard Triple Therapy (7-14 days):** PPI + Amoxicillin (1g) + Clarithromycin (500mg) – all twice daily. * **Bismuth Quadruple Therapy:** PPI + Bismuth + Metronidazole + Tetracycline (Preferred in areas with high Clarithromycin resistance). * **Sequential Therapy:** 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole. * **Test of Cure:** Always performed at least **4 weeks** after completion of therapy and **2 weeks** after stopping PPIs.

Q: A small amount of atropine is added to diphenoxylate in order to:

Discourage overdose and abuse of diphenoxylate. **Explanation:** The correct answer is **D. Discourage overdose and abuse of diphenoxylate.** **Medical Concept:** Diphenoxylate is a potent opioid derivative used as an anti-diarrheal agent. Because it is structurally related to pethidine, it has the potential for CNS effects (euphoria) and physical dependence if taken in high doses. To prevent its misuse, it is formulated as **Lomotil**, which contains a sub-therapeutic (sub-maximal) dose of **Atropine** (0.025 mg) added to Diphenoxylate (2.5 mg). If a person attempts to take a large quantity of the drug to achieve a "high," they will simultaneously ingest a toxic amount of atropine. This results in unpleasant anticholinergic side effects such as tachycardia, dry mouth, blurred vision, and urinary retention, thereby acting as a **deterrent to abuse.** **Analysis of Incorrect Options:** * **A & B:** While atropine has mild anti-emetic and anti-spasmodic (anti-motility) properties, the dose added to diphenoxylate is too small to provide significant clinical synergy or therapeutic benefit for vomiting/diarrhea. * **C:** Atropine does not block the side effects of diphenoxylate; in fact, at high doses, it adds its own toxic profile to the clinical picture. **High-Yield Clinical Pearls for NEET-PG:** * **Loperamide vs. Diphenoxylate:** Unlike diphenoxylate, **Loperamide** does not cross the blood-brain barrier significantly (due to P-glycoprotein efflux) and has negligible abuse potential; hence, it does not require atropine addition. * **Treatment of Overdose:** In cases of diphenoxylate overdose, one must manage both opioid toxicity (with **Naloxone** [1]) and potential anticholinergic crisis. * **Contraindication:** Avoid anti-motility agents in infectious diarrhea (e.g., *Salmonella*, *Shigella*) as they may delay the clearance of toxins and lead to toxic megacolon.

Q: Which drug blocks basal as well as stimulated gastric acid secretion without affecting cholinergic, histaminergic, or gastrin receptors?

Omeprazole. ### Explanation The correct answer is **Omeprazole**. **Mechanism of Action:** Omeprazole is a **Proton Pump Inhibitor (PPI)**. It acts by irreversibly inhibiting the **H+/K+ ATPase enzyme** (the "proton pump") located on the apical membrane of gastric parietal cells. Since this pump is the **final common pathway** for acid secretion, PPIs effectively block acid production triggered by *all* stimuli (Food, Gastrin, Histamine, and Acetylcholine) as well as basal secretion. Crucially, PPIs do not bind to or interfere with the receptors themselves; they act downstream at the enzymatic level. **Analysis of Incorrect Options:** * **Loxatidine & Famotidine (Options A & D):** These are **H2-receptor antagonists**. They specifically block the histamine (H2) receptor. While they reduce acid secretion, they do not block the pathways mediated by Gastrin or Acetylcholine, making them less potent than PPIs. * **Pirenzepine (Option B):** This is a selective **M1-anticholinergic** drug. It blocks the cholinergic stimulation of acid secretion but has no effect on histaminergic or gastrin-induced pathways. **High-Yield NEET-PG Pearls:** * **Drug of Choice:** PPIs are the DOC for Peptic Ulcer Disease (PUD), GERD, and Zollinger-Ellison Syndrome. * **Pharmacokinetics:** PPIs are **prodrugs**, administered as enteric-coated formulations to prevent degradation by stomach acid. They are absorbed in the small intestine and activated in the acidic environment of the **canaliculi** of parietal cells. * **Administration:** They should be taken **30–60 minutes before breakfast** for maximum efficacy, as the number of H+/K+ ATPase pumps is highest after a period of fasting.

Q: What is the most important receptor involved in chemotherapy-induced vomiting?

Serotonin 5-HT3 receptor. ### Explanation **Correct Answer: B. Serotonin 5-HT3 receptor** **Why it is correct:** Chemotherapy-induced nausea and vomiting (CINV) primarily occur through two pathways: the **peripheral pathway** (GI tract) and the **central pathway** (Area Postrema/Chemoreceptor Trigger Zone). Cytotoxic drugs damage the enterochromaffin cells in the GI mucosa, leading to a massive release of **Serotonin (5-HT)**. This serotonin binds to **5-HT3 receptors** on vagal afferent nerves, which transmit signals to the vomiting center in the medulla. 5-HT3 receptor antagonists (e.g., Ondansetron) are the first-line agents for preventing acute CINV because they block this primary trigger. **Why the other options are incorrect:** * **A. Histamine H1 receptor:** These receptors are primarily involved in **motion sickness** and vestibular disorders. H1 blockers like Promethazine are ineffective for CINV. * **C. Dopamine D2 receptor:** While D2 receptors in the CTZ play a role in drug-induced vomiting (e.g., opioids or metabolic toxins), they are secondary to 5-HT3 in the context of highly emetogenic chemotherapy. * **D. Opioid µ receptor:** Activation of these receptors actually *induces* nausea and slows gastric motility; they are not a target for antiemetic therapy. **NEET-PG High-Yield Pearls:** * **Ondansetron** is the drug of choice for **acute** CINV (first 24 hours). * **Aprepitant** (NK1 receptor antagonist) is the drug of choice for **delayed** CINV (after 24 hours), often caused by Cisplatin. * **Palonosetron** is a second-generation 5-HT3 antagonist with a longer half-life, effective for both acute and delayed phases. * **Side effect of 5-HT3 blockers:** Headache and QT interval prolongation (except Palonosetron).

Q: Which of the following is NOT a pharmacologic therapeutic option for achalasia?

Beta blockers. ### Explanation **Achalasia cardia** is a primary esophageal motility disorder characterized by the failure of the Lower Esophageal Sphincter (LES) to relax and the absence of esophageal peristalsis. The primary pharmacologic goal is to **reduce the resting LES pressure** to facilitate the passage of food. #### Why Beta Blockers are the Correct Answer: **Beta blockers (Option B)** have no significant role in the treatment of achalasia. In fact, beta-adrenergic stimulation (specifically $\beta_2$ receptors) typically promotes smooth muscle relaxation. Blocking these receptors would theoretically increase or maintain muscle tone rather than relax the LES. Therefore, they are not a therapeutic option. #### Analysis of Other Options: * **Nitrates (Option A):** Drugs like Isosorbide dinitrate act as nitric oxide donors. Nitric oxide is the primary inhibitory neurotransmitter that mediates LES relaxation. They are used as short-term temporizing measures. * **Botulinum Toxin (Option C):** Injected endoscopically into the LES, it inhibits the release of acetylcholine from excitatory neurons. This shift in neurochemical balance leads to a decrease in LES muscle tone. * **Sildenafil (Option D):** As a PDE-5 inhibitor, sildenafil increases intracellular cGMP levels in smooth muscles, leading to relaxation. It has been shown to effectively lower LES pressure in achalasia patients. #### NEET-PG High-Yield Pearls: * **First-line Medical Therapy:** Calcium Channel Blockers (e.g., **Nifedipine**) are the most commonly used oral agents for achalasia. * **Gold Standard Diagnosis:** Esophageal Manometry (shows "incomplete LES relaxation" and "aperistalsis"). * **Radiology:** "Bird-beak" appearance on Barium swallow. * **Definitive Treatment:** Heller’s Myotomy or Peroral Endoscopic Myotomy (POEM) are preferred over long-term pharmacotherapy, which is usually reserved for patients who are poor surgical candidates.

Question 1

Which of the following drugs does NOT decrease gastric acid secretion?

Accepted Answer

Sucralfate

Answer

Ranitidine

Answer

Omeprazole

Answer

Pirenzepine

Question 2

Which of the following drugs used in the management of peptic ulcers can cause gynecomastia?

Accepted Answer

Cimetidine

Answer

Sucralfate

Answer

Pirenzepine

Answer

Rabeprazole

Question 3

Which drug is used to manage Cisplatin-induced nausea and vomiting occurring within 24 hours?

Accepted Answer

Ondansetron

Answer

Aprepitant

Answer

Fosaprepitant

Answer

Promethazine

Question 4

A 27-year-old woman occasionally uses calcium carbonate for 'heartburn' symptoms after a large meal. What is the mechanism of action of the prescribed medication for an acid-peptic disorder?

Accepted Answer

Neutralizes gastric acid

Answer

Binds to cysteine

Answer

Inhibits gastrin release

Answer

Irreversible H1-receptor blockade

Question 5

Which of the following medications is used to treat opioid-induced constipation?

Accepted Answer

Alvimopan

Answer

Loperamide

Answer

Biperiden

Answer

Naltrexone

Question 6

Which of the following is TRUE regarding anti-H. pylori therapy EXCEPT?

Accepted Answer

It is indicated in all patients with peptic ulcer disease.

Answer

Resistance to any single antimicrobial drug develops rapidly.

Answer

Concurrent suppression of gastric acid enhances the efficacy of the regimen.

Answer

Colloidal bismuth directly inhibits H. pylori but has poor patient acceptability.

Question 7

A small amount of atropine is added to diphenoxylate in order to:

Accepted Answer

Discourage overdose and abuse of diphenoxylate

Answer

Suppress associated vomiting of gastroenteritis

Answer

Augment the anti-motility action of diphenoxylate

Answer

Block side effects of diphenoxylate

Question 8

Which drug blocks basal as well as stimulated gastric acid secretion without affecting cholinergic, histaminergic, or gastrin receptors?

Accepted Answer

Omeprazole

Answer

Loxatidine

Answer

Pirenzepine

Answer

Famotidine

Question 9

What is the most important receptor involved in chemotherapy-induced vomiting?

Accepted Answer

Serotonin 5-HT3 receptor

Answer

Histamine H1 receptor

Answer

Dopamine D2 receptor

Answer

Opioid µ receptor

Question 10

Which of the following is NOT a pharmacologic therapeutic option for achalasia?

Accepted Answer

Beta blockers

Answer

Nitrates

Answer

Botulinum toxin

Answer

Sildenafil

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?